Pharming Group N.V. (PHAR)
Makes protein replacement therapies to treat rare genetic diseases.
$12.86-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+17.3%
The outlook
PHAR is trading well below its 50- and 200-day averages and sits near the lower end of its 52-week range. The stock carries a notably high trailing P/E of 67.7, while analyst price targets average about 167% above the current price. Overall sentiment leans bearish despite the bullish targets, reflecting caution around current valuation and momentum.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range28% of the way from its 52-week low to high
Price targetAvg target +167% vs current price
Analyst price target
~12-month · 4 analysts$34.35average target+167.1% vs now
Now $12.86
Low $23.40High $40.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$908.2M
52-wk high
$21.34
52-wk low
$9.54
50-day avg
$13.12
200-day avg
$15.52
Trailing P/E
67.7